Former Trump FDA Head Allegedly Bypasses Longtime Officials

FDA Leadership Changes and Booster Shot Data Requests

The Wall Street Journal recently reported that FDA Commissioner Marty McCurry and his new vaccine chief have ousted long-standing officials in a recent move to require additional data to back the Covid-19 booster shot.

McCurry and Vinay Prasad, the Director of the Center for Biologics Evaluation and Research, introduced a new framework indicating the necessity for stronger evidence concerning booster shots for healthy adults and children. This marks a shift from the Biden administration’s previous approach of frequent booster doses.

This framework was put forth without any input from the FDA’s career staff, according to the WSJ. Notably, officials at the FDA expect that vaccine manufacturers will not obtain approval for a new Covid-19 booster for healthy individuals without conducting new clinical trials. In comparison, many affluent nations like the UK and Australia have decided against recommending booster shots for these populations.

Some FDA officials are contemplating leaving the pharmaceutical industry under this new leadership, as reported by the WSJ. There has been a notable exodus of drug judges in recent months, which suggests they are engaged in discussions with drug manufacturers regarding new positions. Meanwhile, McCurry is attempting to uplift staff morale, as seen in new FDA podcasts.

The Department of Health and Human Services did not respond right away to requests for comments.

In a separate editorial published on June 10 in the American Medical Association’s journal, McCurry and Prasad expressed their commitment to enhancing the FDA’s monitoring of drug side effects via “big data.” They believe that such post-approval surveillance can help detect safety signals in real time and evaluate the real-world effectiveness of vaccines.

Former Director Peter Marks resigned from the FDA earlier this year, citing concerns about what he called “unprecedented attacks on scientific truths” surrounding vaccines.

Interestingly, a recent Senate investigation highlighted that Marks and other veteran FDA officials had overlooked the risks of myocarditis and pericarditis associated with the Covid vaccination. This was initially flagged by the CDC back in February 2021, but it took months for FDA officials to issue formal warnings, according to a Senate committee report.

This development follows reforms by the CDC Advisory Committee on Immunization Practices (ACIP), which were sparked by concerns regarding the connections of its members to the pharmaceutical industry.